# Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

> **NCT02446743** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 531 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)

## Key facts

- **NCT ID:** NCT02446743
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-17
- **Primary completion:** 2016-09-23
- **Final completion:** 2016-09-23
- **Target enrollment:** 531 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446743, "Combined Study - Phase 3b MenB Long Term Persistence in Adolescents". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02446743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*